- Home
- ACRS vs STRW Comparison
ACRS vs STRW Comparison
Compare ACRS & STRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- STRW
- Stock Information
- Founded
- ACRS 2012
- STRW 2015
- Country
- ACRS United States
- STRW United States
- Employees
- ACRS N/A
- STRW N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- STRW Real Estate Investment Trusts
- Sector
- ACRS Health Care
- STRW Real Estate
- Exchange
- ACRS Nasdaq
- STRW Nasdaq
- Market Cap
- ACRS 165.7M
- STRW 133.6M
- IPO Year
- ACRS 2015
- STRW N/A
- Fundamental
- Price
- ACRS $1.59
- STRW $10.23
- Analyst Decision
- ACRS Strong Buy
- STRW Strong Buy
- Analyst Count
- ACRS 9
- STRW 4
- Target Price
- ACRS $9.25
- STRW $12.72
- AVG Volume (30 Days)
- ACRS 1.3M
- STRW 62.5K
- Earning Date
- ACRS 08-06-2025
- STRW 08-11-2025
- Dividend Yield
- ACRS N/A
- STRW 5.51%
- EPS Growth
- ACRS N/A
- STRW 34.22
- EPS
- ACRS N/A
- STRW 0.58
- Revenue
- ACRS $17,777,000.00
- STRW $126,557,000.00
- Revenue This Year
- ACRS N/A
- STRW $15.21
- Revenue Next Year
- ACRS $11.77
- STRW $2.21
- P/E Ratio
- ACRS N/A
- STRW $17.63
- Revenue Growth
- ACRS N/A
- STRW 22.41
- 52 Week Low
- ACRS $1.05
- STRW $8.70
- 52 Week High
- ACRS $5.17
- STRW $12.90
- Technical
- Relative Strength Index (RSI)
- ACRS 59.88
- STRW 45.21
- Support Level
- ACRS $1.44
- STRW $9.87
- Resistance Level
- ACRS $1.52
- STRW $11.14
- Average True Range (ATR)
- ACRS 0.10
- STRW 0.41
- MACD
- ACRS 0.00
- STRW -0.06
- Stochastic Oscillator
- ACRS 79.17
- STRW 28.12
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.